https://doi.org/10.4081/aiua.2026.14705
Initial safety and efficacy of holmium laser enucleation of the prostate: real world evidence from a tertiary centre
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 8 May 2026
Objective: This study aims to evaluate the initial safety and efficacy of Holmium enucleation of the prostate (HoLEP) in managing benign prostatic hypertrophy (BPH) in a single tertiary centre.
Materials & methods :A retrospective cohort study was conducted focusing on a single tertiary hospital in which data was collected from electronic medical records which includes demographic information, preoperative characteristics, surgical details, and post-operative outcomes; complications were classified using the Clavien-Dindo classification.
Results: 104 patients with BPH and lower urinary tract symptoms (LUTS) were analysed in this study, with a mean prostate volume of 109.3 ± 47.2 ml. The mean change in post void residual volume (PVR) was (-)75%, whilst the mean change in maximum flow rate (QMax) was (+)109%. 21/104 (19%) patients presented with post-operative complications, the majority of these (13) were Grade I complications with three patients being Grade III. Increasing age (p = 0.014) was shown to have contributed to complications. Pre-operative anticoagulation was shown to yield no significance (p = 0.066).
Conclusion: HoLEP remains a viable treatment modality for BPH especially in larger prostates (> 100 ml). However, considerations regarding post-operative outcomes should be taken when offering this treatment to more elderly patients. Additionally, HoLEP provides a good treatment option for patients on anticoagulation.
Downloads
1. National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: assessment and management (Internet). London: NICE; 2010 (updated 2015; cited 2025 Feb 28).
2. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004; 64:1081-8.
3. Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg. 2007; 94:1201-8.
4. Elmansy HM, Kotb A, Elhilali MM. Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup. J Urol. 2011; 186:1972-6.
5. Cornu JN, Ahyai S, Bachmann A, et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract SymptomsnResulting from Benign Prostatic Obstruction: An Update. Eur Urol 2015; 67:1066-1096.
6. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240:205-13.
7. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010; 58:384-97.
8. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol. 2015; 67:1066-1096
9. Gilling PJ, Kennett K M, Fraundorfer MR, & Holmium Study Group. Holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP) in a prospective randomized trial with 2-year follow-up. J Endourol 2012; 26: 343-349
10. Shah HN, Mahajan AP, Hegde SS, & Mahajan AS. Perioperative outcomes of holmium laser enucleation of prostate in patients on anticoagulant therapy: A comparative study. J Endourol 2016; 30:850-855.
11. El Tayeb MM, Jacob JM, Bhojani N, et al. Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation. J Endourol. 2016; 30:805-9.
12. Naspro R, Suardi N, Salonia A, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates > 70 g: 24- month follow-up. Eur Urol. 2006; 50:563-8.
13. Elsaqa M, Zhang Y, El M. MP51-07 Impact of Age and frailty on surgical outcomes of Holmium laser enucleation of prostate (HoLEP) in nonagenarians and octagenarians patients. J Urol. 2023; 209(Suppl 4):e695.
14. Placer J, Gelabert-Mas A, Vallmanya F, et al. Holmium laser enucleation of the prostate: Outcome and complications of self-taught learning curve. World J Urol 2016; 34:555-562.
15. Montorsi F, Naspro R, Salonia A, et al. Holmium laser enucleation of the prostate for benign prostatic hyperplasia: indications and techniques. Journal of Endourology. 2016; 30:115-121.
16. Mmeje CO, Nunez-Nateras R, Warner JN, Humphreys MR. Age-stratified outcomes of holmium laser enucleation of the prostate. BJU Int. 2013; 112:982-9.
17. Rieken M, Cornu JN, Gilling P, et al. Risk factors for intraoperative complications in patients undergoing prostate enucleation with holmium laser: results from a large international multicentre study. World Journal of Urology. 2014; 32:421-427.
18. Nam JK, Kim HW, Lee DH, et al. Risk Factors for Transient Urinary Incontinence after Holmium Laser Enucleation of the Prostate. World J Mens Health. 2015; 33:88-94.
19. Roper C, Slade A, Caras R, et al. Ejaculatory and erectile function outcomes following holmium laser enucleation of the prostate. Prostate. 2024; 84:791-796.
20. Savin Z, Dekalo S, Herzberg H, et al. Improving Prostatic Preoperative Volume Estimation and Planning before Laser Enucleation. J Pers Med. 2022; 12:1761.
Supporting Agencies
nonHow to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.